# Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

> **NCT00019929** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** mutant p53 peptide pulsed dendritic cell vaccine
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00019929
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019929, "Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00019929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*